doctor on phone - Referrals for Clinicians

How We Work With Healthcare Providers

In our experience, patients are best served when the all members of the provider team work together and are fully informed. We value your expertise and welcome the opportunity to support you and your patients.

Submit your referral

We Work With:

Psychiatrists
Therapists
Psychologists
Neurologists
Pain Specialists
Primary Care Physicians
Coaches
Social Workers

Treatments for:

Depression
Anxiety
PTSD
Migraines & Headaches
CRPS & Chronic Pain
Immunity & Resilience

Our Services:

IV Ketamine
Spravato (intranasal Ketamine)
Stellate Ganglion Blocks (SGB)
IV Nutrients & Vitamins
IV NAD+
IV Glutathione
Ketamine Assisted Psychotherapy (KAP)
Life Skills Coaching

Let us help you support your patients!

We pride ourselves on offering our patients a process that is administratively efficient and clinically rigorous while maintining a high level of personalized care and attention.

Step 1: Confirm Your Patient's Interest

The first step is to confirm your patient's openness/interest in infusion therapies such as Ketamine, NAD+, Vitamins, Glutathione, etc. by having a conversation with the differences between Combination Infusion Therapy and conventional approaches to treating anxiety, depression and PTSD.

Step 2: Submit Online Patient Referral Form

If you believe your patient may be a good fit for guided Ketamine treatments, then please tell us a little about them so we may contact them. You can submit a Patient Referral Form here.

Step 3: Review Patient Care Plan With Us

Once we have spoken with your patient and received required documents, we will contact you to confirm/discuss our treatment plan. We value your input and experience and will work closely with you to ensure the best patient care possible.

Step 4: We Provide Ongoing Updates About Treatments and Progress

With your patient's consent, we will share treatment information with you in order to keep you informed of their progress.

Research Papers

How NAD+ Can Treat Degenerative Diseases

December 6, 2016

More recently it has been found that NAD+ is also required as a substrate by enzymes that regulate the expression of genes involved in cell viability and aging and in repair of damaged DNA.

Ketamine for the Treatment of Chronic Migraines

November 22, 2016

Intravenous (IV) ketamine has been previously used to treat various refractory pain conditions. We present a series of patients with refractory migraine treated with intravenous ketamine in the hospital setting.

Screen Shot 2021-02-11 at 11.05.32 AM - Referrals for Clinicians

How Ketamine Cures Depression: The Science Behind It

June 30, 2016

Like many other drugs, ketamine has multiple effects rendering it suitable for various indications including anesthesia, sedation, acute and chronic pain relief and treatment of therapy-resistant depression.

Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal Cortex

March 13, 2016

A single subanesthetic dose of ketamine, an NMDA receptor antagonist, leads to fast-acting antidepressant effects.

Portrait of woman holding black and white younger photo of herself - Referrals for Clinicians

Changes in Oxidative Damage, Inflammation and [NAD(H)] with Age

January 14, 2014

High levels of oxidative damage results in key cellular changes including a reduction in available nicotinamide adenine dinucleotide (NAD+), an essential molecule required for a number of vital cellular processes including DNA repair, immune signaling and epigenetic processing.

Artificial-Synapse - Referrals for Clinicians

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression

October 1, 2013

Ketamine, a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion. The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression.

Ketamine to Treat Obsessive-Compulsive Disorder (OCD)

July 17, 2013

As converging evidence suggests a role for the glutamate system in the pathophysiology of OCD, we tested whether a single dose of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, could achieve rapid antiobsessional effects.

Screen Shot 2021-02-11 at 11.51.52 AM - Referrals for Clinicians

Ketamine and Depression: From Despair to Hope in Hours

April 4, 2013

Carlos Zarate, M.D., speeds up treatment for major depression at the National Institutes of Health (NIH) Intramural Research Program (IRP). Dr. Zarate is Chief of the Experimental Therapeutics & Pathophysiology Branch and the Section on the Neurobiology and Treatment of Mood Disorders at the National Institute of Mental Health (NIMH).

« Previous
1
…
5
6
7
8
Next »